US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

118.42

+1.821.56%

Volume:6K

Turnover:680.76K

Market Cap:103.02M

PE:- -

High:118.42

Open:117.15

Low:117.15

Close:116.60

52wk High:126.40

52wk Low:55.34

Shares:870.00K

Float Shares:870.00K

Volume Ratio:0.62

T/O Rate:0.67%

Dividend:0.33

Dividend Rate:0.28%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

Political and General News Events from August 28

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026

Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.

AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BIB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"ProShares Ultra Nasdaq Biotechnology","latestPrice":118.415,"timestamp":1788291772216,"preClose":116.5968,"halted":0,"volume":5793,"delay":0,"changeRate":0.015593909952931851,"floatShares":870000,"shares":870000,"eps":0,"marketStatus":"Trading","change":1.8182,"latestTime":"09-01 15:44:14 EDT","open":117.15,"high":118.415,"low":117.15,"amount":680759.06544,"amplitude":0.010849,"askPrice":118.53,"askSize":220,"bidPrice":118.26,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":116.5968,"sharesOutstanding":1040000,"nav":116.3208,"aum":101199096,"dividendRate":0.002752,"bidAskSpread":0.003041,"preHourTrading":{"tag":"盘前","latestPrice":117.83,"preClose":116.5968,"latestTime":"08:59 EDT","volume":13,"amount":1531.79,"timestamp":1788267571078,"change":1.2332,"changeRate":0.010577,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":116.6,"preClose":116.5968,"latestTime":"19:30 EDT","volume":13,"amount":1515.464,"timestamp":1788219002070,"change":0.0032,"changeRate":0.000027,"amplitude":0},"volumeRatio":0.616642,"impliedVol":0.4385,"impliedVolPercentile":0.4444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","floatShares":870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.616642,"shares":870000,"dividePrice":0.3259,"high":118.415,"amplitude":0.010849,"preClose":116.5968,"low":117.15,"week52Low":55.34,"pbRate":"--","week52High":126.399,"institutionHeld":0,"latestPrice":118.415,"committee":-0.375,"eps":0,"divideRate":0.002752,"volume":5793,"delay":0,"ttmEps":0,"open":117.15,"prevYearClose":79.7794,"prevWeekClose":116.3898,"prevMonthClose":116.5968,"prevQuarterClose":100.74,"fiveDayClose":125.1901,"twentyDayClose":100.17,"sixtyDayClose":80.2719},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIB\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"BIB","amount":0.00714,"announcedDate":"2026-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-25","defaultRemindTime":1774445400000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-25","currency":"USD","dateTimestamp":1774411200000,"payDate":"2026-03-31"},{"date":"2025-12-24","symbol":"BIB","amount":0.134637,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-31"},{"date":"2025-09-24","symbol":"BIB","amount":0.180541,"announcedDate":"2025-09-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-24","defaultRemindTime":1758720600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-24","currency":"USD","dateTimestamp":1758686400000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"BIB","amount":0.170576,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-07-01"},{"date":"2025-03-26","symbol":"BIB","amount":0.130939,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-04-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIB\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-22","recordDate":"2022-12-23","paymentDate":"2022-12-30","value":0.019852,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-28","value":0.038393,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-27","value":0.040324,"currency":"USD"},{"executeDate":"2024-06-26","recordDate":"2024-06-26","paymentDate":"2024-07-03","value":0.26476,"currency":"USD"},{"executeDate":"2024-09-25","recordDate":"2024-09-25","paymentDate":"2024-10-02","value":0.15285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663015807","title":"Amgen Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663015807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663015807?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:34","pubTimestamp":1787949240,"startTime":"0","endTime":"0","summary":"DJ Amgen Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  slipped 1.05% to $432.42 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,711.76 and Dow Jones Industrial Average  falling 0.02% to 53,559.99.This was the stock's fourth consecutive day of losses.Amgen Inc. closed 3.27% below its 52-week high of $447.03, which the company reached on August 25th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  rose 0.85% to $268.04, Pfizer Inc.  fell 0.21% to $27.96, and AbbVie Inc.  fell 1.03% to $255.48.Trading volume  remained 889,592 below its 50-day average volume of 2.6 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 28, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU0109394709.USD","LU1061106388.HKD","LU0889565916.HKD","LU1571399168.USD","BK4581","LU0320765992.SGD","LU2112291526.USD","IE00B2B36J28.USD","BK4534","IE00BJT1NW94.SGD","IBB","LU0122379950.USD","BK4533","PJP","LU0058720904.USD","LU2089984988.USD","BK4566","BBH","LU0868494617.USD","LU1023059063.AUD","TBXU","SG9999001440.SGD","IE0002141913.USD","LU1983299246.USD","BIB","BK4588","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","PBE","LU1057294990.SGD","IBBQ","LU2242652126.USD","04332","LU0289739699.SGD","IE0009355771.USD","BK4599","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663018885","title":"Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663018885","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663018885?lang=en_us&edition=fundamental","pubTime":"2026-08-29 01:20","pubTimestamp":1787937637,"startTime":"0","endTime":"0","summary":"Gilead Sciences stock was down roughly 2% on Friday alongside an FDA update concerning HIV drug Bixlenvo.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/gilead-sciences-stock-gild-slips-2-despite-fda-approval-of-bixlenvo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/gilead-sciences-stock-gild-slips-2-despite-fda-approval-of-bixlenvo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","BK4578","LU1571399168.USD","LU1934455863.HKD","IE00BKVL7J92.USD","LU1778281490.HKD","BIB","BK4566","IE00B3T34201.USD","LU1934455194.USD","IBB","BK4585","LU0965509101.SGD","LU1066051498.USD","LU2357627491.SGD","TBXU","BK4139","LU1934455277.USD","SG9999015978.USD","LU1057294990.SGD","LABU","BK4588","LU0823416689.USD","IE00B19Z3581.USD","IBBQ","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2112291526.USD","LU0859254822.USD","BBH","LU0882574055.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","LU1037948897.HKD","BK4532","LU0109394709.USD","LU1674673691.USD","MEDI","TMED","LU0889565916.HKD","BMED","LU0114720955.EUR","LU1037948541.HKD","SG9999015986.USD","LU1066053197.SGD","SG9999015945.SGD","LU1585245621.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663097210","title":"Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663097210","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663097210?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:30","pubTimestamp":1787934634,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. Vertex’s new Phase 1 study, officially titled “A Phase 1, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-tests-vx-407s-impact-on-birth-control-what-it-means-for-vrtx-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-tests-vx-407s-impact-on-birth-control-what-it-means-for-vrtx-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BBH","GNMX","IE0002270589.USD","IE00B19Z3581.USD","PBE","VERX","LU1674673428.USD","LU2237438978.USD","IBBQ","BK4023","LU2362541513.USD","LU2417539215.USD","LU2468319806.SGD","SG9999001176.USD","VRTX","ISBC","LU1585245621.USD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001176.SGD","LU1430594728.SGD","BK4588","LU0566484027.USD","LU0823416689.USD","IDNA","LU2362541273.HKD","BK4532","LU0417517546.SGD","LU0058720904.USD","TBXU","IE0009355771.USD","LU2089984988.USD","SG9999013999.USD","LU1815336091.USD","LU1559883803.SGD","IBB","LU0320765992.SGD","BK4211","BIB","LU2324357040.USD","IE00B894F039.SGD","LU1093756325.SGD","IE00BJT1NW94.SGD","BK4567","IE00B19Z9Z06.USD","LU2362540622.SGD","BK4139","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663225097","title":"Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663225097","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663225097?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:30","pubTimestamp":1787934627,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest psoriasis study update spotlights apremilast (AMG 407) for ki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-wrap-up-what-apremilast-safety-data-means-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-pediatric-psoriasis-study-wrap-up-what-apremilast-safety-data-means-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242652126.USD","LU2242646821.SGD","BBH","PBE","BIB","LU2468319806.SGD","AMGN","IE0009355771.USD","BK4533","IBBQ","LU1023059063.AUD","LU1057294990.SGD","BK4599","BK4139","SG9999001440.SGD","TBXU","IE00BFTCPJ56.SGD","BK4581","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","IE0002141913.USD","LU1061106388.HKD","LU0058720904.USD","BK4211","LU0122379950.USD","BK4566","LU1571399168.USD","BK4534","LU0289739699.SGD","LU1983299246.USD","BK4588","IBB","LU0889565916.HKD","ISBC","LU0868494617.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU2112291526.USD","LU0320765992.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098405","title":"Political and General News Events from August 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098405?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:30","pubTimestamp":1787920229,"startTime":"0","endTime":"0","summary":"DIARY-Political and General News Events from August 28Aug 28 (Reuters)-For other diaries, please see:Political andGeneral NewsPOL/DIARYTop Economic EventsM/DIARYEmerging Markets Economic EventsEMRG/DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4N44P0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0320765992.SGD","LU2468319806.SGD","BK4566","LU0289739699.SGD","IBBQ","BK4581","BK4533","PBE","BK4599","IE0002141913.USD","IE0009355771.USD","TBXU","LU1571399168.USD","LU0122379950.USD","LU0109394709.USD","SG9999001440.SGD","LU1061106388.HKD","LU0889565916.HKD","IE00B4R5TH58.HKD","AMGN","BK4585","LU2089984988.USD","BK4534","BK4139","LU1057294990.SGD","BIB","PJP","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","LU2242652126.USD","BBH","LU1023059063.AUD","BK4588","IBB","IE00B2B36J28.USD","LU0058720904.USD","LU2112291526.USD","IE00BJT1NW94.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762030","title":"Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762030","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662762030?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:17","pubTimestamp":1787883449,"startTime":"0","endTime":"0","summary":"Gilead breaks ground on Foster City biologics facility in $32 billion US investment pushGilead broke ground on its Chess biologics facility at its Foster City, California headquarters as part of a pla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL98vB5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0965509101.SGD","LU1674673428.USD","BK4532","LU0823416689.USD","IBB","LU1066053197.SGD","LU1934455194.USD","LU2357627491.SGD","BBH","BK4568","LU0289739699.SGD","LU0861579265.USD","LU1066051498.USD","BK4588","LU2112291526.USD","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU1037948897.HKD","IE00BKVL7J92.USD","BIB","LU0965508806.USD","LU1057294990.SGD","LU1430594728.SGD","LU0859254822.USD","IE00B19Z3581.USD","LU1037948541.HKD","SG9999015952.SGD","TMED","LU0109394709.USD","IE0002270589.USD","BK4578","IE00B7SZLL34.SGD","IBBQ","GILD","LU0058720904.USD","LU1061106388.HKD","LU0320765992.SGD","MEDI","BMED","LU1674673691.USD","BK4583","LU2087621335.USD","LU2324357040.USD","LU0965509283.SGD","TBXU","LU0965509010.AUD","LU1934455863.HKD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662394370","title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662394370","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662394370?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:45","pubTimestamp":1787870729,"startTime":"0","endTime":"0","summary":"Gilead Sciences director Anthony Welters disposes of USD 2.64 million in common sharesGilead director Anthony Welters exercised stock options for 18,000 shares on Aug. 26, 2026 at prices of USD 60.67 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL29Bbzm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0889565916.HKD","LU0122379950.USD","GILD","BK4583","LU1571399168.USD","LU1037948897.HKD","MEDI","BK4588","TBXU","LU1057294990.SGD","LU0965509101.SGD","IE00BSNM7G36.USD","BIB","LU0289739699.SGD","IE00B3T34201.USD","LU0109394709.USD","LU1061106388.HKD","BK4578","IE00B19Z3B42.SGD","BK4139","BK4585","LU1066051498.USD","LU1934455863.HKD","LU1023059063.AUD","BK4568","LU0965508806.USD","LU1430594728.SGD","LU2324357040.USD","IBB","LU0058720904.USD","TMED","IBBQ","IE00B7SZLL34.SGD","LU0965509010.AUD","LU2087621335.USD","LU0861579265.USD","BK4566","IE0002270589.USD","LU0859254822.USD","LU1674673428.USD","LU1839511570.USD","BMED","LU2112291526.USD","LU1585245621.USD","LU0320765992.SGD","SG9999015986.USD","BBH","BK4532","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036059","title":"Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036059","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036059?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:55","pubTimestamp":1787867719,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gileads-bixlenvo-approved-by-fda-for-virologically-suppressed-adults-with-hiv-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BSNM7G36.USD","LABU","LU0965509101.SGD","LU1674673428.USD","BK4532","LU0823416689.USD","IBB","LU1066053197.SGD","LU1934455194.USD","LU2357627491.SGD","BBH","BK4568","SG9999015986.USD","LU0861579265.USD","LU1066051498.USD","BK4588","LU0234570918.USD","LU0889565916.HKD","LU1037948897.HKD","BIB","IE00BZ1G4Q59.USD","LU1057294990.SGD","LU0859254822.USD","IE00B19Z3581.USD","BK4566","SG9999015952.SGD","TMED","LU0109394709.USD","LU1839511570.USD","IBBQ","GILD","LU0058720904.USD","LU1023059063.AUD","LU1061106388.HKD","MEDI","IE00B19Z3B42.SGD","LU1585245621.USD","BK4585","BMED","LU1674673691.USD","BK4583","LU2087621335.USD","SG9999015945.SGD","LU2324357040.USD","LU0965509283.SGD","TBXU","LU1571399168.USD","LU0122379950.USD","LU1934455863.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036301","title":"US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036301","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036301?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867441,"startTime":"0","endTime":"0","summary":"US FDA approves Gilead's once-daily combination pill for HIV treatmentAug 27 -The U.S. Food and Drug Administration has approved Gilead Sciences'GILD.Oonce daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O24M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU1674673428.USD","IBB","LU2357627491.SGD","BBH","LU0289739699.SGD","LU0861579265.USD","LU1066051498.USD","BK4588","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU1037948897.HKD","BIB","IE00BZ1G4Q59.USD","LU0965508806.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU1037948541.HKD","BK4566","LU1934455277.USD","SG9999015952.SGD","TMED","IE00B3T34201.USD","LU1839511570.USD","IE0002270589.USD","BK4578","IE00B7SZLL34.SGD","IBBQ","GILD","LU0058720904.USD","LU0882574055.USD","LU1023059063.AUD","LU1061106388.HKD","LU0320765992.SGD","MEDI","LU1778281490.HKD","IE00B19Z3B42.SGD","LU1585245621.USD","BK4585","BMED","BK4583","LU0114720955.EUR","SG9999015945.SGD","LU2324357040.USD","TBXU","LU0965509010.AUD","LU0122379950.USD","LU1934455863.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036807","title":"U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036807?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:47","pubTimestamp":1787867220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA7M9KZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1778281490.HKD","GILD","LU0882574055.USD","BK4588","LU1934455194.USD","BK4566","BK4583","LU1934455277.USD","LU1934455863.HKD","TMED","LU1061106388.HKD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU2089984988.USD","SG9999015978.USD","BK4550","LU1066053197.SGD","LU2468319806.SGD","LU1066051498.USD","BK4578","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU1571399168.USD","IBBQ","LU0289739699.SGD","LU1057294990.SGD","MEDI","LU0234570918.USD","LU0861579265.USD","TBXU","IE00B3T34201.USD","LU2087621335.USD","BK4568","LU0965509283.SGD","BK4585","LU0965509010.AUD","LU1037948897.HKD","IBB","BMED","LU1430594728.SGD","IE00B19Z3B42.SGD","LU1839511570.USD","LU0889565916.HKD","BK4532","BBH","LU0823416689.USD","IE00BKVL7J92.USD","BIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0861579265.USD","BK4583","BBH","LU1934455277.USD","LGHT","LU0889565916.HKD","BK4533","MRNY","LU1061106388.HKD","BK4534","IBBQ","LU1037948541.HKD","LU1674673691.USD","IE00BKVL7J92.USD","MRNA","LU0320765992.SGD","LU0114720955.EUR","LU1571399168.USD","LU1674673428.USD","TMED","LU1066053197.SGD","LU2468319806.SGD","BK4568","BK4139","LU0965508806.USD","IDNA","BK4550","SG9999015952.SGD","SG9999015986.USD","GNOM","MEDI","GILD","IBB","LU1934455194.USD","MRNX","LU0109394709.USD","BIB","BK4588","IE00B7SZLL34.SGD","BMED","IE00B19Z3581.USD","LU2324357040.USD","LU0965509283.SGD","LU2357627491.SGD","SG9999015945.SGD","LU0965509010.AUD","BK4551","WDNA","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4139","LU2242652126.USD","IE0009355771.USD","PBE","IE00B2B36J28.USD","AMGN","LU1983299246.USD","BK4588","LU0109394709.USD","LU0889565916.HKD","LU1061106388.HKD","BK4566","SG9999001440.SGD","LU2242646821.SGD","PJP","LU0289739699.SGD","TBXU","IBBQ","LU0320765992.SGD","BK4533","BBC","BBH","LU0122379950.USD","LU2089984988.USD","BK4534","IE00B4R5TH58.HKD","LU0868494617.USD","LU0058720904.USD","BK4599","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","LU1057294990.SGD","LU1571399168.USD","LU2112291526.USD","BK4581","LU1023059063.AUD","BK4585","IBB","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","IE00B4R5TH58.HKD","BK4137","HCSG","LU2242646821.SGD","LU1571399168.USD","BK4585","SG9999001440.SGD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","LABU","LU0128526141.USD","BK4599","BBH","LU0868494617.USD","LU0058720904.USD","LU2468319806.SGD","IE0002141913.USD","XLV","BK4588","LU0320765992.SGD","LU0122379950.USD","AMGN","LU1023059063.AUD","LU2112291526.USD","PBE","LU0889565916.HKD","TBXU","LU1983299246.USD","LU0289739699.SGD","VRCA","PJP","LU0109394709.USD","LU1057294990.SGD","BK4533","IE00B2B36J28.USD","LU2089984988.USD","BK4581","IBB","IBBQ","XBI","LU2242652126.USD","BK4534","IE00BJT1NW94.SGD","BK4566","IE00BJJMRZ35.SGD","LU0029874061.USD","BK4007","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","PJP","LU0109394709.USD","IBBQ","02142","LU1061106388.HKD","LU1983299246.USD","BK1161","BK4585","BIB","BK4566","LU0289739699.SGD","BK4588","IE00B2B36J28.USD","LU0058720904.USD","LU1023059063.AUD","AMGN","IE0002141913.USD","PBE","SG9999001440.SGD","IE00BFTCPJ56.SGD","BK4139","IE00BJJMRZ35.SGD","BK4533","LU2242652126.USD","BK4581","BK1574","LU2468319806.SGD","LU0320765992.SGD","BK4599","LU0122379950.USD","LU1571399168.USD","IE0009355771.USD","IBB","LU1057294990.SGD","BBH","TBXU","LU2112291526.USD","BK1583","BK4534","LU0889565916.HKD","LU0868494617.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","LU0708994859.HKD","IE0002141913.USD","LU2236285917.USD","BK4533","BK4007","IE00BJT1NW94.SGD","LU2456880835.USD","LU0029864427.USD","LU1829250122.USD","BK4534","LU0432979614.USD","LU1267930573.SGD","LU2237443382.USD","BK4588","LU0122379950.USD","LU2089984988.USD","PBE","BBH","AZN","PJP","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2417539215.USD","LU2462157665.USD","AZNH","LU2237443622.USD","LU2237443465.HKD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0868494617.USD","BK4139","BIB","TBXU","LU0128525929.USD","BK4568","IE0009355771.USD","BK4581","LU0289739699.SGD","BK4566","IBB","BK4585","LU2242646821.SGD","IE00B3T34201.USD","AMGN","IE00B2B36J28.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","LU0432979614.USD","LU2242646821.SGD","IE00B3T34201.USD","LU0122379950.USD","PBE","IBB","LU0889565916.HKD","LU0289739699.SGD","BK4007","LU0128525929.USD","LU1267930573.SGD","LU2236285917.USD","LU2237443978.SGD","BK4566","BK4568","IE0009355771.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","TBXU","LU0058720904.USD","IE0002141913.USD","BIB","LU0868494617.USD","IBBQ","AMGN","IE00B2B36J28.USD","AZNH","LU2417539215.USD","BBH","LU1571399168.USD","BK4581","LU0320765992.SGD","PJP","LU2468319806.SGD","BK4585","LU1023059063.AUD","LU2237443895.HKD","LU2456880835.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU1829250122.USD","AZN","LU1061106388.HKD","BK4588","BK4533","LU0029864427.USD","LU1057294990.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TBXU","AZNH","IE00B4R5TH58.HKD","BK4534","LU2462157665.USD","LU2237443622.USD","LU2242652126.USD","LU0058720904.USD","LU0889565916.HKD","BBH","LU2242646821.SGD","BK4533","PJP","LU0708994859.HKD","BK4585","LU2089984988.USD","LU2237443465.HKD","LU1057294990.SGD","LU1061106388.HKD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","LU0128525929.USD","LU1267930573.SGD","BK4566","IE00BJT1NW94.SGD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","LU1829250122.USD","BK4599","LU0029864427.USD","LU0310800379.SGD","AMGN","BIB","BK4581","IBBQ","AZN","IBB","LU0109394709.USD","LU2237443382.USD","LU0868494617.USD","LU1571399168.USD","IE00B2B36J28.USD","PBE","BK4007","LU2237443549.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775710","title":"Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775710?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813720,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has been selected as a constituent of the JPX-Nikkei Mid and Small Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","SG9999001176.USD","IE0002141913.USD","SG9999013999.USD","BK4533","IE00BJT1NW94.SGD","SGXZ57979304.SGD","LU2456880835.USD","LU0432979614.USD","IE00B19Z9Z06.USD","LU1585245621.USD","BK4532","IDNA","LU1430594728.SGD","LU1069344957.HKD","LU2089984988.USD","LU1559883803.SGD","PBE","VERX","BBH","LU0823416689.USD","LU0109394709.USD","LU0566484027.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU2417539215.USD","LU2462157665.USD","JPX","LU1815336091.USD","BK4567","LU2468319806.SGD","VRTX","IE00BFTCPJ56.SGD","GNMX","IE00B19Z9P08.USD","IE00B4R5TH58.HKD","BK4023","BIB","TBXU","LU0289739699.SGD","LU0234570918.USD","IBB","BK4585","IE00BZ9MQY76.HKD","LU1778281490.HKD","LU0079474960.USD","IE00B2B36J28.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662477574","title":"Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662477574","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662477574?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813711,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has updated its earlier disclosures on changes to directors and offic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","LU1815336091.USD","LU0320765992.SGD","SG9999001176.USD","TBXU","VRTX","BK4532","LU0058720904.USD","LU2362541273.HKD","BBH","LU2462157665.USD","GNMX","LU0234570918.USD","BK4139","LU1035775433.USD","BIB","LU1559883803.SGD","IE00B19Z9P08.USD","BK4585","LU2362541513.USD","LU0566484027.USD","IE00BZ9MQY76.HKD","BK4567","LU1674673428.USD","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0417517546.SGD","LU0256863811.USD","IBBQ","LU0889565916.HKD","IE00BJT1NW94.SGD","BK4533","LU1430594728.SGD","LU2417539215.USD","SGXZ57979304.SGD","IE0002270589.USD","IBB","LU0061475181.USD","LU0289739699.SGD","LU0757428866.USD","VERX","LU0823416689.USD","LU2456880835.USD","LU1093756325.SGD","IDNA","IE00B19Z3581.USD","LU0079474960.USD","LU2236285917.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662514775","title":"AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662514775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662514775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:40","pubTimestamp":1787812818,"startTime":"0","endTime":"0","summary":"UPDATE 3-AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trialAug 27 (Reuters)-AstraZenecaAZN.Lsaid on Thursday its asthma drug Tezspire met the main goals of a late-stage tria","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","BBH","AMGN","LU0792757196.USD","LU1974910355.USD","LU2293690082.USD","AZN.UK","LU0310799852.SGD","TBXU","REGN","LU2237443382.USD","LU1267930490.SGD","LU0972486137.USD","LU1153584641.USD","LU0661504455.SGD","LU1880407132.USD","LU0640478417.SGD","LU0047473722.EUR","LU0052756011.USD","LU0823434583.USD","LU0997586515.USD","LU1119994496.HKD","03165","LU1170363599.USD","LU1481600234.SGD","IBB","IE00BFTCPJ56.SGD","LU3187612489.SGD","LU0738911758.USD","LU2242652126.USD","PBE","SGXZ57979304.SGD","BK4588","LU0345777659.USD","LU1057294990.SGD","LU1051770623.HKD","LU0266013472.USD","LU1003077747.HKD","LU2237443622.USD","PJP","LU0575583348.USD","LU0432979614.USD","BK4599","LU1571399168.USD","LU1829250122.USD","LU0077335932.USD","LU0997586432.USD","LU0887340254.USD","LU0122379950.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}